Besides that, some authors had explored the potential association between the SULT1A1 polymorphism and breast cancer risk and it had also shown inconsistent results. Kotnis’ study showed that the polymorphism of SULT1A1 Arg213His might predispose carriers to lung cancers, protect against colorectal cancers and increase the risk of breast cancer to Asian women but not the Caucasian women [11]. Recently Wang et al. meta-analyzed the relationships between SULT1A1 and breast cancer risk [12] and concluded
that there was no significant relationship between SULT1A1 R213 H polymorphism and the risk of breast cancer. However both meta-analysis were not perfect and may lead to underestimate Adavosertib order the role of mTOR inhibitor SULT1A1 polymorphism in breast carcinogenesis, because they did not include some eligible studies and neglected the valuable subgroup analysis such as menopausal status. It should be pointed out that there was new finding in results of the present study which was never founded in the previous. The
current meta-analysis approved to be a more precise estimation which included two more studies and a subgroup analysis according to menses status which came out statistical significance. Here we performed an updated meta-analysis which was specialized in breast cancer, including 16 studies with a subgroup analysis based on ethnicity and menopausal status, using Arg/Arg vs His/His, Arg/Arg vs Arg/His, dominant model (Arg/His+His/His vs Arg/Arg) and recessive model (His/His vs Arg/Arg+Arg/His). Protein Tyrosine Kinase inhibitor Methods Identification and analysis of relevant studies Two investigators (Yiwei Jang and Liheng Zhou) independently obtained relevant articles through searches of PubMed, EBSCO and Web of Science databases using the following words: ‘sulfotransferase or SULT’, ‘polymorphism’ and ‘breast cancer’. Studies had been case-control design and based on SULT1A1 Arg213His polymorphism either alone
or in combination with other genes Staurosporine and the language of publication was restricted to English. All of the studies required study design, publication, breast cancer cases, controls selection and genotyping methods. We excluded articles on only breast cancer patients or on healthy persons and one case-series study. In the end, 10362 breast cancer patients and 14250 controls from 16 case-control studies were selected for this meta-analysis. Data extraction The following data were collected from each included studies: first authors, year of publications, study population (categorized as Asian, Caucasian, African and others), sources of controls, menopausal status and the number of different genotype in all subjects.